MSJ0010.1177/1352458515574149Multiple Sclerosis JournalPanditet al.
MULTIPLE SCLEROSIS MSJ JOURNAL
Letter
NS NS 0.0009 NS NS NS
1–2 DOI: 10.1177/ 1352458515574149
34 27 59 68 79 55
0.15 0.11 0.02 0.11 0.09 0.06
0.06 0.05 0.10 0.11 0.13 0.09
4.49 4.35 0.40 1.73 1.19 1.28
1.41 1.36 0.07 0.58 0.38 0.35
14.3 13.97 2.33 5.18 3.75 4.71
0.01 0.03 0.0001 0.99 0.20 0.39
© The Author(s), 2015. Reprints and permissions: http://www.sagepub.co.uk/ journalsPermissions.nav
24 19 14 15 16 14 *10 *12 *13 *14 *15:01 *15:02
Ca-Freq: Case frequency, Co-Freq: Control frequency, Hi: High, IgG: immunoglobulin G, Lo:Low, OR: odds ratio.
13 10 2 10 8 6 NS NS NS NS NS NS 0.003 0.009 0.32 0.16 0.05 0.43 5.63 5.93 2.02 1.82 1.60 2.18 1.16 1.09 0.36 0.35 0.33 0.39 2.55 2.54 0.86 0.80 0.73 0.92 0.06 0.05 0.09 0.11 0.13 0.09 0.12 0.10 0.07 0.08 0.09 0.08
13 22 13 18 *01 *03 *04 *07
34 27 59 68 79 55
0.25 0.001 0.001 0.02 1 32.46 2.41 2.99 1 2.62 0.15 0.25 1 9.23 0.61 0.86 0.08 0.02 0.13 0.14 0.05 0.13 0.05 0.07 47 14 77 82 4 11 4 6 NS 0.00009 NS NS 0.71 0.00001 0.01 0.09 1 13.5 1.37 1.82 1 2.39 0.27 0.35 1 5.69 0.61 0.79 0.08 0.02 0.13 0.14 0.07 0.11 0.06 0.09
95% Hi 95% Lo OR Co-Freq Ca-Freq Control Case DRB1
47 14 77 82
pcorrected puncorrected 95% Hi 95% Lo OR Co-Freq Ca-Freq Control Case pcorrected puncorrected
Ninety three consecutive patients (24 males and 69 females) with relapsing Neuromyelitis optica spectrum disorders (NMO/NMOS) disorders including 61 NMO (Wingerchuck 2006 criteria6), 11 recurrent myelitis with long cord lesions, 20 recurrent optic neuritis and one patient with recurrent tumefactive demyelination were studied. For genotyping patient samples were compared with 300 MS patients who fulfilled McDonald criteria7 and an equal number of healthy unrelated controls. Anti-AQP4 antibody was detected by fixed cell based assay using a commercially available kit (EUROIMMUN, Germany). HLA-DR typing was performed by polymerase chain reaction with sequence specific primers. Alleles that were DRB1*1501/1502 positive by this low resolution typing technique were sequenced for accurately determining HLA-DRB1*1501 status. The study was approved by the institutional ethics committee. HLA-DRB1 allele frequencies between patients and healthy volunteers were evaluated using UNPHASED3.0.8. Bonferroni–Dunn’s correction was applied to uncorrected p values. A corrected p value (cp)
MULTIPLE SCLEROSIS MSJ JOURNAL
Letter
NS NS 0.0009 NS NS NS
1–2 DOI: 10.1177/ 1352458515574149
34 27 59 68 79 55
0.15 0.11 0.02 0.11 0.09 0.06
0.06 0.05 0.10 0.11 0.13 0.09
4.49 4.35 0.40 1.73 1.19 1.28
1.41 1.36 0.07 0.58 0.38 0.35
14.3 13.97 2.33 5.18 3.75 4.71
0.01 0.03 0.0001 0.99 0.20 0.39
© The Author(s), 2015. Reprints and permissions: http://www.sagepub.co.uk/ journalsPermissions.nav
24 19 14 15 16 14 *10 *12 *13 *14 *15:01 *15:02
Ca-Freq: Case frequency, Co-Freq: Control frequency, Hi: High, IgG: immunoglobulin G, Lo:Low, OR: odds ratio.
13 10 2 10 8 6 NS NS NS NS NS NS 0.003 0.009 0.32 0.16 0.05 0.43 5.63 5.93 2.02 1.82 1.60 2.18 1.16 1.09 0.36 0.35 0.33 0.39 2.55 2.54 0.86 0.80 0.73 0.92 0.06 0.05 0.09 0.11 0.13 0.09 0.12 0.10 0.07 0.08 0.09 0.08
13 22 13 18 *01 *03 *04 *07
34 27 59 68 79 55
0.25 0.001 0.001 0.02 1 32.46 2.41 2.99 1 2.62 0.15 0.25 1 9.23 0.61 0.86 0.08 0.02 0.13 0.14 0.05 0.13 0.05 0.07 47 14 77 82 4 11 4 6 NS 0.00009 NS NS 0.71 0.00001 0.01 0.09 1 13.5 1.37 1.82 1 2.39 0.27 0.35 1 5.69 0.61 0.79 0.08 0.02 0.13 0.14 0.07 0.11 0.06 0.09
95% Hi 95% Lo OR Co-Freq Ca-Freq Control Case DRB1
47 14 77 82
pcorrected puncorrected 95% Hi 95% Lo OR Co-Freq Ca-Freq Control Case pcorrected puncorrected
Ninety three consecutive patients (24 males and 69 females) with relapsing Neuromyelitis optica spectrum disorders (NMO/NMOS) disorders including 61 NMO (Wingerchuck 2006 criteria6), 11 recurrent myelitis with long cord lesions, 20 recurrent optic neuritis and one patient with recurrent tumefactive demyelination were studied. For genotyping patient samples were compared with 300 MS patients who fulfilled McDonald criteria7 and an equal number of healthy unrelated controls. Anti-AQP4 antibody was detected by fixed cell based assay using a commercially available kit (EUROIMMUN, Germany). HLA-DR typing was performed by polymerase chain reaction with sequence specific primers. Alleles that were DRB1*1501/1502 positive by this low resolution typing technique were sequenced for accurately determining HLA-DRB1*1501 status. The study was approved by the institutional ethics committee. HLA-DRB1 allele frequencies between patients and healthy volunteers were evaluated using UNPHASED3.0.8. Bonferroni–Dunn’s correction was applied to uncorrected p values. A corrected p value (cp)
